Picture of Purple Biotech logo

PPBT Purple Biotech Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapValue Trap

Annual cashflow statement for Purple Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

R2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:20-F20-F20-F20-F20-F
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-28.7-17.8-21.8-20-7.28
Depreciation
Non-Cash Items18.11.61.57-0.419-2.94
Discontinued Operations
Unusual Items
Other Non-Cash Items
Changes in Working Capital-3.440.7443.250.274-4.33
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Cash from Operating Activities-13.8-15.3-16.7-19.9-14.4
Capital Expenditures-0.156-0.115-0.228-0.0030
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-49.413.520.113.90.509
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-49.613.419.913.90.509
Financing Cash Flow Items-5.38-0.099-0.219-0.946-0.6
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities68.51.511.115.456.77
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash5.16-0.3574.14-0.541-7.09